University of Vermont

The University of Vermont Cancer Center

This page has moved to here!

trials_mela.html

Melanoma Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on skin cancer research.

Status: Active - Recruiting

Study Title: EA6141- Study Title for Study Participants: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma

Purpose: The randomized phase II/III trial studies the side effects and best dose of nivolumaband ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with sage III-IV melanoma that cannot be removed by surgery.
ClinicalTrials.gov Identifier: NCT02339571
Contact: Jane Walsh (802) 656-9926
Information: https://clinicaltrials.gov/ct2/show/NCT02339571?term=EA6141&rank=1
Institution Number: CHRMS 16-580 EA6141
Protocol Research Type: Cooperative Group
Status: Active - Recruiting

Study Title: A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Purpose: This is a 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation.
ClinicalTrials.gov Identifier: NCT01909453
Contact: Jane Walsh (802) 656-9926
Information: https://clinicaltrials.gov/ct2/show/NCT01909453?term=CMEK&rank=12
Institution Number: 14-174
Protocol Research Type: Industry Sponsored
Status: Active - Closed to Accrual

Study Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Purpose: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.  In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Steven Emmons, MD
Contact: Jane Walsh (802) 656-9926
Information: N/A
Institution Number: M12-125 ECOG-ACRIN 1609
Protocol Research Type: Cooperative Group - ECOG-ACRIN

Last modified December 02 2016 09:39 AM